Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - misoprostol, quantity: 200 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; hydrogenated castor oil; microcrystalline cellulose; hypromellose - cytotec is indicated in the treatment of acute duodenal and gastric ulcers. cytotec is indicated for the prevention of stress-induced upper gastrointestinal mucosal bleeding and lesions in post-surgical patients in intensive care units. cytotec is indicated for the prevention of gastric ulceration in patients in whom nsaid therapy is essential and who have been assessed at high risk of gastric ulceration, or the complications of gastric ulceration.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 400; maize starch; hypromellose; calcium sulfate dihydrate; povidone; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit; flavour - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 25 mg - tablet, film coated - excipient ingredients: macrogol 400; hypromellose; maize starch; calcium sulfate dihydrate; magnesium stearate; povidone; flavour; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 1 mg; mestranol, quantity: 51.5 microgram - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; maize starch; magnesium stearate - indications as at 23rd january 1998: oral contraception. norinyl-1 is an agent for conception control.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 350 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - indications as at 9 march 2003 : noriday is an oral contraceptive for women who will not, or cannot tolerate other oral contraceptives or intrauterine devices.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

searle -

Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet

Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet - 25 mg

Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet - 100 mg

Egypt - English - EDA (Egyptian Drug Authority)

searle-canada - tablet